As low prevalence rate of the disease, target accrual in clinical trials has been a bottleneck in gallbladder cancer, our study forms the basis to include gallbladder patients for an anti‐EGFR therapy under basket clinical trials such as the NCI–Molecular Analysis for Therapy Choice (NCI‐MATCH) trials that are genomically matched.56 This evidence concerns the gene EGFR and gallbladder cancer.